Generation Investment Management noted in its Q2 2026 investor letter that West Pharmaceutical Services (NYSE:WST) received its highest internal business quality rating of 1. The company is a leading manufacturer of packaging and delivery systems for injectable drugs and healthcare products. Its products represent a small but critical component of the cost of finished pharmaceuticals, and it holds approximately three-quarters of the "high-value products" market, supplying over 90% of newly approved drugs. As of September 4, WST closed at $339.97, with a market capitalization of $23.93 billion. Its stock price has risen 34.30% over the past 52 weeks and declined 3.45% in the last month.